Home > Haematology > ASH 2020 > Multiple Myeloma > High symptom burden in transplant-ineligible patients with newly diagnosed MM

High symptom burden in transplant-ineligible patients with newly diagnosed MM

Presented By
Dr Hira Mian, McMaster University, Canada
Conference
ASH 2020
“Despite many advances in therapeutics, transplant-ineligible patients with multiple myeloma (MM) still experience high symptom burden,” Dr Hira Mian (McMaster University, Canada) stated. “Our results demonstrate that this is especially the case during the first 3 months following diagnosis. Although there is an improvement, even at the 1-year mark, a significant symptom burden remained.” Patient-reported outcomes (PROs) represent an opportunity to both understand the magnitude as well as the temporal trend of symptom burden. The presented study investigated PROs, assessed by the Edmonton Symptoms Assessment System (ESAS) scores, from transplant-ineligible patients with newly diagnosed MM [1]. ESAS is a validated outcome tool assessing the severity of 9 common cancer-associated symptoms: well-being, pain, tiredness, anxiety, depression, drowsiness, lack of appetite, nausea, and shortness of breath. Patients report symptoms from 0 (no symptoms) to 10 (worst...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on